ReviewFrontiers in immunology2026
Precision medicine in rheumatoid arthritis: advances and clinical applications of multi-omics biomarkers.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a highly heterogeneous autoimmune disease characterized by the presence of synovitis, joint destruction, and systemic inflammation. Despite the substantial improvement in patient outcomes brought about by the advent of targeted therapies, the traditional "one-size-fits-all" treatment model still faces numerous challenges. These include individual variability in treatment response, a "trial-and-error" process in drug selection, and the emergence of refractory RA. Precision medicine is the development of optimal prevention and treatment strategies based on patients' individual characteristics (including genetic, environmental, and lifestyle factors). This new approach offers a way to address the therapeutic challenges of RA. Multi-omics biomarkers, which integrate data from multiple dimensions including genomics, transcriptomics, proteomics, metabolomics, and epigenomics, are central tools for achieving precision medicine in RA. This article reviews the current status and challenges of precision medicine for RA, systematically summarizing the latest research advances in multi-omics biomarkers regarding RA pathogenesis, early diagnosis, treatment response prediction, prognosis assessment, and risk stratification of complications. The primary focus of this research is the identification of novel biomarkers [including TAOK3 and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.